A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354
Recruiting
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +16 locations
Conditions: Multiple Myeloma
Register for Updates
Accuracy of Metagenomic Blood Sampling to Identify Pathogen in Infective Endocarditis Patients
NCT06309680
Recruiting
Infective Endocarditis is an infection, usually a bacterium, which attacks the heart and can cause valves to leak and produces a bacterial mass which can break off from the valves and block the blood supply to important organs. We are very keen to improve the treatment of this disease and we are measuring the impact of the treatments that we give to patients so that we have a very clear idea of which treatments work best and also which treatments are less successful. A key part of the treatmen... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: St Bartholomew's Hospital. West Smithfield, London, Not set
Conditions: Infective Endocarditis
Register for Updates
Yoga Nidra for Insomnia and Posttraumatic Stress Symptoms
NCT06888336
Recruiting
This randomized feasibility study is designed to investigate the feasibility of recruitment and delivery of two variations (brief; full) of a virtual Integrative Restoration (iRest) yoga nidra meditation intervention in stressor- or trauma-exposed participants with insomnia and posttraumatic stress symptoms, compared to a waitlist control group. Feasibility will also be examined for data collection (daily sleep diaries and PTSD symptom surveys) and at-home polysomnography (PSG) study completion... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
03/17/2025
Locations: University College London, London, Not set
Conditions: Posttraumatic Stress Disorder (PTSD), Insomnia, Stressor, Psychological, Psychological Trauma
Register for Updates
Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases
NCT06891365
Recruiting
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of NNC0581-0001 in participants with hepatic steatosis and suspected steatohepatitis (increased liver fat and suspected inflammation). NNC0581-0001 will be given in 2 different dose levels as injection under the skin (once per month for 3 months). Participants will either get NNC0581-001 or Placebo (dummy treatment). Which treatment participants get is decided by chance. NNC0581-0001 is a new medicine which ca... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/17/2025
Locations: Parexel CPRU, Level 7, Harrow, Not set
Conditions: Healthy Volunteers, Hepatic Steatosis
Register for Updates
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
NCT05819866
Recruiting
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Stanford University Medical Center, Palo Alto, California +12 locations
Conditions: Cerebral Adrenoleukodystrophy (cALD)
Register for Updates
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
NCT06892860
Recruiting
This is an adaptive, open-label, randomised phase II trial that aims to evaluate the impact of 3 vs 6 cycles of first-line platinum-based chemotherapy followed by maintenance avelumab in the quality of life of patients with locally advanced or metastatic urothelial cancer. Initially, 224 eligible and evaluable patients (112 in each arm) will receive 3 cycles vs 6 cycles of 3-weekly gemcitabine plus cisplatin/carboplatin, followed by 2-weekly maintenance avelumab until disease progression or into... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Unicancer, Paris, Not set +2 locations
Conditions: Urinary Bladder Neoplasms
Register for Updates
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT04379596
Recruiting
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients. Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or immunotherapy administered to subjects at the recommended phase 2 dose will sho... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2025
Locations: Research Site, Santa Monica, California +99 locations
Conditions: Gastric Cancer
Register for Updates
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
NCT04408625
Recruiting
Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years.... Read More
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
03/14/2025
Locations: k2 Medical Research-Maitland, Maitland, Florida +10 locations
Conditions: Frontotemporal Dementia
Register for Updates
An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection
NCT04494412
Recruiting
Influenza infection is an important public health priority, with seasonal outbreaks and pandemics causing considerable global morbidity and mortality. The PK, pharmacodynamics (PD), safety and efficacy of IV zanamivir have been evaluated in adults, adolescents and infants more than or equal to (\>=) 6 months of age with hospitalized influenza in the IV zanamivir global development program. However, antiviral treatment of neonates and infants under 6 months of age hospitalized with influenza infe... Read More
Gender:
ALL
Ages:
6 months and below
Trial Updated:
03/14/2025
Locations: GSK Investigational Site, Firenze, Not set +8 locations
Conditions: Influenza, Human, Arthralgia
Register for Updates
THERApy De-escalation for TESTicular Cancer
NCT06309745
Recruiting
THERATEST is looking to collect data from 30 patients actively receiving de-escalation treatments or other standard of care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether we should proceed with these treatments in a larger study, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study... Read More
Gender:
MALE
Ages:
16 years and above
Trial Updated:
03/14/2025
Locations: Barts and London Hospital NHS Trust, London, Not set
Conditions: Seminoma
Register for Updates
HPV Self-testing in Transgender Individuals
NCT05883111
Recruiting
Human papillomavirus (HPV) is a common virus that spreads through skin-to-skin contact. Some HPV types can cause changes in cells that lead to cancer and are known as 'high-risk' HPV (hrHPV). hrHPV is linked to cancers of the cervix (opening of the womb), throat, and anus (exit of the bowel). It is not known if transgender people (individuals whose gender identity does not align with their sex assigned at birth) are at increased risk of hrHPV or cancers caused by hrHPV compared to cisgender peo... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/14/2025
Locations: University Hospitals Sussex NHS Foundation Trust Sexual Health Service, Brighton, Not set +2 locations
Conditions: HPV Infection
Register for Updates
A Novel COMBinATorial Therapy with Albumin and Enoxaparin in Patients with Decompensated Cirrhosis At High-risk of Poor Outcome (COMBAT Trial).
NCT05895136
Recruiting
The goal of this clinical trial is to determine primarily whether a combinatorial therapy based on the administration of human albumin and enoxaparin is safe and effective in patients with decompensated cirrhosis discharged from the hospital. The main questions it aims to answer are: * Is this combinatorial therapy safe and tolerable? * Is this combinatorial therapy effective? * does this combinatorial therapy cost more or less than standard medical therapy? Participants will attend to study vi... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/14/2025
Locations: Hôpital Beaujon, Clichy, Not set +8 locations
Conditions: Liver Cirrhosis, Decompensated Cirrhosis of Liver, Acute on Chronic Liver Failure (ACLF)
Register for Updates